Schlott, F.* ; Steubl, D.* ; Ameres, S. ; Moosmann, A. ; Dreher, S.* ; Heemann, U.* ; Hösel, V.* ; Busch, D.H.* ; Neuenhahn, M.*
     
 
    
        
Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8+ T cells.
    
    
        
    
    
        
        PLoS ONE 13:e0193554 (2018)
    
    
    
		
		
			
				Human Cytomegalovirus (CMV) reactivation remains a major source of morbidity in patients after solid organ and hematopoietic stem cell transplantation (HSCT). Adoptive T cell therapy (ACT) with CMV-specific T cells is a promising therapeutic approach for HSCT recipients, but might be counteracted by CMV's immune evasion strategies. HLA-C*07:02 is less susceptible to viral immune evasion suggesting HLA-C*07:02-restricted viral epitopes as promising targets for ACT. For a better understanding of HLA-C*07: 02-restricted CMV-specific T cells we used recently generated reversible HLA-C*07:02/IE-1 multimers (Streptamers) recognizing a CMV-derived Immediate-Early-1 (IE-1) epitope and analyzed phenotypic and functional T cell characteristics. Initially, we detected very high frequencies of HLA-C*07:02/IE-1 multimer(+) T cells (median = 11.35%), as well as robust functional responses after stimulation with IE-1 peptide (IFN gamma(+); median = 5.02%) in healthy individuals. However, MHC-multimer(+) and IFN gamma-secreting T cell frequencies showed a relatively weak correlation (r(2) = 0.77), which could be attributed to an unexpected contribution of CMV-epitope-independent KIR2DL2/3-binding of HLA-C*07:02/IE-1 multimers. Therefore, we developed a MHC-multimer double-staining approach against a cancer epitope-specific HLA-C* 07: 02 multimer to identify truly HLA-C*07:02/IE-1 epitope-specific T cells. The frequencies of these truly HLA-C*07:02/IE-1 multimer(+) T cells were still high (median = 6.86%) and correlated now strongly (r(2) = 0.96) with IFN gamma-secretion. Interestingly, HLA-C*07:02/IE-1-restricted T cells contain substantial numbers with a central memory T cell phenotype, indicating high expansion potential e.g. for ACT. In line with that, we developed a clinical enrichment protocol avoiding epitope-independent KIR-binding to make HLA-C* 07: 02/IE-1-restricted T cells available for ACT. Initial depletion of KIR-expressing CD8(+) T cells followed by HLA-C*07:02/IE-1 Streptamer positive selection using paramagnetic labeling techniques allowed to enrich successfully HL-AC* 07:02/IE-1-restricted T cells. Such specifically enriched populations of functional HL-AC* 07:02/IE-1-restricted T cells with significant central memory T cell content could become a potent source for ACT.
			
			
				
			
		 
		
			
				
					
					Impact Factor
					Scopus SNIP
					Web of Science
Times Cited
					Scopus
Cited By
					
					Altmetric
					
				 
				
			 
		 
		
     
    
        Publikationstyp
        Artikel: Journalartikel
    
 
    
        Dokumenttyp
        Wissenschaftlicher Artikel
    
 
    
        Typ der Hochschulschrift
        
    
 
    
        Herausgeber
        
    
    
        Schlagwörter
        Stem-cell; Kidney-transplantation; Adoptive Transfer; Immunity; Lymphocytes; Infection; Cmv; Donor; Recipients; Receptors
    
 
    
        Keywords plus
        
    
 
    
    
        Sprache
        
    
 
    
        Veröffentlichungsjahr
        2018
    
 
    
        Prepublished im Jahr 
        
    
 
    
        HGF-Berichtsjahr
        2018
    
 
    
    
        ISSN (print) / ISBN
        1932-6203
    
 
    
        e-ISSN
        
    
 
    
        ISBN
        
    
 
    
        Bandtitel
        
    
 
    
        Konferenztitel
        
    
 
	
        Konferzenzdatum
        
    
     
	
        Konferenzort
        
    
 
	
        Konferenzband
        
    
 
     
		
    
        Quellenangaben
        
	    Band: 13,  
	    Heft: 2,  
	    Seiten: ,  
	    Artikelnummer: e0193554 
	    Supplement: ,  
	
    
 
  
        
            Reihe
            
        
 
        
            Verlag
            Public Library of Science (PLoS)
        
 
        
            Verlagsort
            Lawrence, Kan.
        
 
	
        
            Tag d. mündl. Prüfung
            0000-00-00
        
 
        
            Betreuer
            
        
 
        
            Gutachter
            
        
 
        
            Prüfer
            
        
 
        
            Topic
            
        
 
	
        
            Hochschule
            
        
 
        
            Hochschulort
            
        
 
        
            Fakultät
            
        
 
    
        
            Veröffentlichungsdatum
            0000-00-00
        
 
         
        
            Anmeldedatum
            0000-00-00
        
 
        
            Anmelder/Inhaber
            
        
 
        
            weitere Inhaber
            
        
 
        
            Anmeldeland
            
        
 
        
            Priorität
            
        
 
    
        Begutachtungsstatus
        Peer reviewed
    
 
     
    
        POF Topic(s)
        30203 - Molecular Targets and Therapies
    
 
    
        Forschungsfeld(er)
        Immune Response and Infection
    
 
    
        PSP-Element(e)
        G-501500-001
    
 
    
        Förderungen
        
    
 
    
        Copyright
        
    
 	
    
    
    
    
    
        Erfassungsdatum
        2018-05-22